AOTI, Inc.

Director's Dealing • Jul 31, 2025

National Storage Mechanism | Additional information

RNS Number : 4139T

AOTI, Inc.

31 July 2025

31 July 2025

AOTI Inc.

(the "Company")

Director/PDMR Shareholding - Share purchase

The Company was informed on 31 July 2025 that Mr Jayesh Pankhania, Chief Financial Officer of the Company, bought a total of 310,000 common shares of $0.00001 in the capital of the Company ("Common Shares") at 50 pence per share and 64,289 Common Shares at 58 pence per share.

Following the purchase, Mr Pankhania's beneficial holding and the total interest in the Company has increased to 405,539 Common Shares, representing approximately 0.38% of the Company's issued share capital.

The below notification, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them  

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jayesh Pankhania

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

AOTI Inc.

b)

LEI

213800ZGCNDSTWIRK687

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Common shares of $0.00001 each

ISIN: US03690C1027

b)

Nature of the transaction

Purchase of Common Shares by Mr Pankhania on 31 July 2025

c)

Price(s) and volume(s)

Price(s)	Volume(s)
50p	310,000
58p	64,289

d)

Aggregated information

- Aggregated volume

- Price

NA

NA

e)

Date of the transaction

31 July 2025

f)

Place of the transaction

London Stock Exchange

For further information please contact:

AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer	+44 (0)20 3727 1000 ir@aotinc.net
Peel Hunt LLP (Nominated Adviser and Broker) Dr. Christopher Golden, James Steel	+44 (0)20 7418 8900
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins, Alex Davis	+44 (0)20 3727 1000 AOTI@fticonsulting.com

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2 ®) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalizations and 71 per cent reduction in amputations over 12 months. TWO2 ® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2 ® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see  www.aotinc.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBGGDRBGXDGUB